News | July 29, 2025
Piramal Pharma reports Q1 FY26 consolidated loss at Rs. 81.70 Cr
Piramal Pharma has reported total income of Rs. 1,992.11 crores during the period ended June 30, 2025
Piramal Pharma has reported total income of Rs. 1,992.11 crores during the period ended June 30, 2025
His experience includes leadership roles in manufacturing, strategic management, and commercial operations across the pharmaceuticals, healthcare, and specialty chemicals sectors
The company reported consolidated EBITDA loss of Rs. 10.5 crore in Q1 FY26 as compared to loss of Rs. 45.3 crore in the same period last year
This year, the OCTF focused on preparing a white paper on oral cancer elimination in India and updating its annual consensus guidelines
Aman holds a bachelor’s degree in economics from Boston University and an MBA from Columbia University, New York
The company has projected Rs. 5,630 crores of investment and to provide employment to 6,350 people in three phases over a period of eight years
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
The latest BioE3 policy builds the framework for high-performance biomanufacturing to propel the development and production
His career spans notable tenures at Syngene International Limited, Cipla, Nestlé, and Bharat Petroleum Corporation Limited
This achievement is part of the population-based initiative for screening, prevention, and management of Non-Communicable Diseases
Subscribe To Our Newsletter & Stay Updated
